Fig. 4From: How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directionsGraphically presented already developed SLN-tailored mAbs by the authors (own drawing). CTAB cetyltrimethylammonium bromide, mAb monoclonal antibody, SLN solid lipid nanoparticles, HER2 human epithelial growth receptor 2, IFX infliximab, ADM adalimumabBack to article page